Physician profile
Jaspreet Kaur
NPI 1184988057
$1,776.14
in general payments reported to CMS, 2019-2025
26 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $84.07 · 2021: $247 · 2022: $127 · 2023: $389 · 2024: $188 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $734 · Education: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $734.46 |
| Education | $248.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $427.86 | 2019-2023 | Xospata |
| Pfizer INC. | $150.27 | 2024-2025 | |
| Seagen INC. | $148.99 | 2023 | |
| Blueprint Medicines Corporation | $133.92 | 2023 | Ayvakit |
| Novo Nordisk INC | $125.97 | 2020-2025 | Ozempic |
| Sobi, INC | $99.99 | 2025 | |
| Abbvie INC. | $61.77 | 2021-2025 | |
| Arbor Pharmaceuticals, INC. | $51.37 | 2020-2021 | |
| Almatica Pharma LLC | $50.76 | 2021 | |
| Glaxosmithkline, LLC. | $49.71 | 2024-2025 | Shingrix |
| Amarin Pharma, INC. | $44.32 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $41.07 | 2020-2021 | |
| Exelixis INC. | $40.89 | 2025 | Cabometyx |
| Kowa Pharmaceuticals America, INC. | $36.97 | 2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $33.42 | 2019-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $33.42 | 2019-2025 | Breztri |
| Lilly USA, LLC | $29.78 | 2022-2025 | Jardiance |
| Pharmaessentia USA Corporation | $28.81 | 2024 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.66 | 2021-2022 | |
| Abbott Laboratories | $28.63 | 2023 | Freestyle Libre 2 |
| Biocon Biologics INC | $28.02 | 2025 | Ogivri |
| Alexion Pharmaceuticals, INC. | $23.68 | 2025 | Ultomiris |
| Mayne Pharma Commercial LLC | $20.45 | 2023 | |
| Exact Sciences Corporation | $19.80 | 2025 | The Cologuard Plus Collection Kit |
| Hologic Sales and Service, LLC | $19.40 | 2019 | |
| Sumitomo Pharma America, INC. | $18.21 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaspreet Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.